Page 2 - Wockhardt

Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years

Shares of Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17% on the BSE in Wednesday's intra-day trade surpassed its previous high of ₹1,678.60 touched on February 6, 2025.

Wockhardt's novel antibiotic Zaynich eyes $9 billion global market

Company to launch Zaynich in India this fiscal; sees $7 bn market in US and EU and ₹17,000 crore in India; USFDA, EU filings underway for FY26

Wockhardt Q4 results: Drug maker's net loss shrinks to Rs 45 crore

Drug firm Wockhardt on Thursday reported a consolidated net loss of Rs 45 crore in the fourth quarter ended March 31, 2025. The drug maker had reported a net loss of Rs 177 crore in the January-March quarter of FY24. Revenue from operations rose to Rs 743 crore in the fourth quarter as compared to Rs 700 crore in the year-ago period, Wockhardt said in a regulatory filing. For FY25, the company said its net loss stood at Rs 57 crore as compared to Rs 472 crore in the year-ago period. Revenue increased to Rs 3,012 crore as compared to Rs 2,798 crore in 2023-24 fiscal. Shares of the company closed at Rs 1,347.75 apiece, 0.63 per cent higher from previous close, on the BSE.

Wockhardt looks to exit US generics biz; tariff burden may hit consumers

Wockhardt is planning to exit the US generics business, while American consumers are expected to bear the impact of tariffs

Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with European Medicines Agency (EMA)

Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria

Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients

Wockhardt rises 5% on getting CDSCO's approval for pneumonia curing drug

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults

Why this pharma stock hit nearly 9-year high; froze at 10% upper circuit?

Wockhardt stock gained 10% to touch Rs 1,536.40; it has outperformed the market by zooming 262% thus far in calendar year 2024, as compared to the 13% rise in the BSE Sensex

Indian pharma develops more effective drug to combat antibiotic-resistance

Wockhardt's nafithromycin is India's first FDA-approved antimicrobial that is seen as an alternative to existing antibiotics like azithromycin, which is facing increasing resistance in humans

Wockhardt Q2 results: Net loss narrows to Rs 16 cr, revenue at Rs 809 cr

Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024. The company has reported a net loss of Rs 73 crore in July-September quarter of last fiscal. Revenue from operations stood at Rs 809 crore for the second quarter as compared with Rs 753 crore in the year-ago period, the Mumbai-based drug maker said in a regulatory filing. Shares of the company were trading 0.63 per cent up at Rs 1,189 apiece on BSE.

This pharma stock has zoomed over 380% in Samvat 2080; trades at 8-yr high

Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.

Wockhardt gains 4% on filing for DCGI's approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Wockhardt locks in 5% upper circuit as it nears approval for pneumonia drug

A positive response from CDSCO will give a push to the company efforts to gain the Drugs Controller General of India's (DCGI) final approval for Miqnaf

Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

Drug firm Wockhardt on Friday said the national drug regulator has accorded a favourable recommendation for its novel antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has provided a favourable recommendation for Miqnaf (nafithromycin), the drug firm said in a statement. The SEC recommendation is based on CDSCO's comprehensive review of the product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over the last 15 years, it added. A positive opinion from the SEC of CDSCO would pave the way for gaining DCGI's final approval for Miqnaf, the company stated. Miqnaf is the once-a-day 3-days-only treatment for CABP patients, including those caused by multi-drug resistant (MDR) bugs. CABP is the most common infection, leading to hospitalisation and death. Globally, 2.4 million annual dea

US FDA grants fast track status to Wockhardt's novel antibiotic WCK 6777

WCK 6777 is a once-a-day, β-lactam enhancer used for outpatient parenteral antimicrobial therapy

Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.

Wockhardt denies Carol Info rent payment allegations, link with Sebi orders

Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company. "In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday. It said the company has acted and continues to act in compliance with all applicable laws. On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt. Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.

Wockhardt falls 5% after Congress alleges Sebi head of conflict of interest

This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Wockhardt, Brigade Ent, Medplus Health among six stocks to watch on May 29

Stocks to watch on May 29: Wockhardt reported its Q4 earnings, disclosing a net loss of Rs 177 crore compared to a loss of Rs 237 crore YoY